Issues with reducing the rotavirus-associated mortality by vaccination in developing countries
- PMID: 18472196
- DOI: 10.1016/j.vaccine.2008.04.004
Issues with reducing the rotavirus-associated mortality by vaccination in developing countries
Abstract
More than 65% of the global rotavirus deaths were estimated to occur in 11 countries in Asia and Africa, claiming 345,000 children less than 5 years of age in 2004. While efficacious rotavirus vaccines are at hand, inequity in health delivery system within and between these countries was found to be the major hurdle against achieving the goal of rotavirus vaccine. When the coverage of currently used vaccines was applied to a rotavirus vaccine, a maximum of 202,550 deaths would be averted. Even if the coverage reached 80%, there would remain 96,841 children dying because of rotavirus diarrhea in these 11 countries. Studies are therefore encouraged to develop comprehensive strategies to resolve inequity in health delivery system enabling the increase in the immunization coverage.
Similar articles
-
Rotavirus vaccines: targeting the developing world.J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6. doi: 10.1086/431504. J Infect Dis. 2005. PMID: 16088799
-
Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions.Vaccine. 2012 Apr 27;30 Suppl 1:A3-6. doi: 10.1016/j.vaccine.2011.10.007. Vaccine. 2012. PMID: 22520133 Review.
-
Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality.Expert Rev Vaccines. 2012 Feb;11(2):211-20. doi: 10.1586/erv.11.184. Expert Rev Vaccines. 2012. PMID: 22309669 Review.
-
Global mortality associated with rotavirus disease among children in 2004.J Infect Dis. 2009 Nov 1;200 Suppl 1:S9-S15. doi: 10.1086/605025. J Infect Dis. 2009. PMID: 19817620 Review.
-
Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.Vaccine. 2009 May 14;27(22):2916-22. doi: 10.1016/j.vaccine.2009.03.016. Epub 2009 Mar 25. Vaccine. 2009. PMID: 19428901
Cited by
-
Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.Hum Vaccin Immunother. 2013 Aug;9(8):1638-42. doi: 10.4161/hv.25076. Epub 2013 Jun 4. Hum Vaccin Immunother. 2013. PMID: 23807360 Free PMC article. Clinical Trial.
-
Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.BMJ. 2009 Sep 25;339:b3653. doi: 10.1136/bmj.b3653. BMJ. 2009. PMID: 19783581 Free PMC article.
-
Surveillance of Human Rotaviruses in Wuhan, China (2019-2022): Whole-Genome Analysis of Emerging DS-1-like G8P[8] Rotavirus.Int J Mol Sci. 2023 Jul 29;24(15):12189. doi: 10.3390/ijms241512189. Int J Mol Sci. 2023. PMID: 37569563 Free PMC article.
-
Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.Paediatr Drugs. 2010 Aug 1;12(4):235-56. doi: 10.2165/11537200-000000000-00000. Paediatr Drugs. 2010. PMID: 20593908 Review.
-
Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi.Vaccine. 2012 Apr 27;30 Suppl 1(0 1):A140-51. doi: 10.1016/j.vaccine.2011.09.119. Vaccine. 2012. PMID: 22520123 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical